Fetal aortic valvuloplasty as the first step in a complex therapeutic strategy

Sofía Grinenco,Horacio Antonio Aiello,César Hernán Meller,Victorio Lucini,Natalia Nápoli,Luis Trentacoste,Antonela Córdoba,Mercedes Saenz Tejeira,Juan Manuel Osuna,Jorge Barretta,Alejandra Beatriz Villa,Pablo Marantz,Lucas Otaño
DOI: https://doi.org/10.1002/pd.6579
2024-04-28
Prenatal Diagnosis
Abstract:Background Fetal aortic valvuloplasty (FAV) is proposed to prevent hypoplastic left heart syndrome due to fetal critical aortic stenosis. Objective: to report our experience on FAV as the first step in a complex therapeutic strategy. Method Series of patients with FAV over an 18‐year period. Results 27 FAVs were performed in 26 fetuses, with technical success in 82% (22/27) and periprocedural fetal demise in 22% (6/27), decreasing to 15% in the second half‐cohort. Loss to follow‐up was due to birth or postnatal therapy in other centers (5) and termination of pregnancy (1), A normal‐sized LV at birth was observed in 46% (6/13), 4 neonates underwent aortic valvuloplasty and 2 cardiac surgeries, with 5/6 achieving biventricular circulation at 28 days, and 3 transplant‐free survival at mid‐term follow‐up. The 7/13 born with a borderline LV underwent LV rehabilitation strategy, with survival at 28 days in 4/7 and at mid‐term in 3: one with biventricular circulation, one with a ventricle‐and‐a‐half repair, and one lost to follow‐up. Conclusion FAV was feasible in most cases, with no maternal complications, and biventricular circulation at 28 days in ∼40% of survivors. After FAV, a diverse range of postnatal cardiac interventions are performed, reflecting the challenging innovation in current cardiovascular therapy.
genetics & heredity,obstetrics & gynecology
What problem does this paper attempt to address?